Aurinia Pharmaceuticals investor relations material

Aurinia is a biopharmaceutical company driven by a relentless commitment to bring life-changing therapies, like voclosporin, to patients suffering from diseases with high unmet medical need. The Company’s lead product, voclosporin, is being investigated as a therapy for LN. The Company is initially targeting LN and has plans to study additional disease indications. The company is headquartered in Victoria, Canada.